Immunovant (NASDAQ:IMVT) Stock, Quote.Headers.trade-ideas

Immunovant

Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

Biotech

Earnings

Earnings Beats

Large Cap

Mid Cap

News

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

FULC

ILMN

IMVT

KRYS

Shares of Immunovant (NASDAQ: IMVT) are rising in the pre-market hours on Sept. 9 after the company announced positive data from the mid-stage study of its investigational candidate, batoclimab, which is being developed for Graves&#39; Disease.

IMVT Stock Up on Upbeat Data From Graves&#39; Disease Study of Batoclimab

ROIV

Health Care

Movers

Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves&#39; Disease, showing a high response rate and significant IgG reduction. A pivotal trial is expected to start by the end of 2024.

What&#39;s Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?

Titoli a dividendo scelti dai migliori analisti di Wall Street

Short Ideas

Pre-Market Outlook

TERN

Top 2 Health Care Stocks That May Collapse This Quarter

Immunovant Inc

Press Releases

Immunovant Provides Update on Graves' Disease Development Program

Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

Immunovant Announces $450 Million Private Placement

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

ROIVW

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

Akero Therapeutics

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Biohaven

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Amicus Therapeutics

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

PTC Therapeutics

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Veracyte

Viking Therapeutics

Zai Lab Limited - American Depositary Shares

Zai Lab

HC Wainwright & Co.

B of A Securities

Wells Fargo

Raymond James

Oppenheimer

Comments

Immunovant

Immunovant (NASDAQ:IMVT) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga